SPI Infoamtion

1 Executive Summary: Global Clinical Trial Business 2008-2018
1.1 Aims of the Global Clinical Trial Business 2008-2018 Report
1.2 Scope of the Global Clinical Trial Business 2008-2018 Report

2 Background Information on Clinical Trials
2.1 Brief History of Code of Conduct for Clinical Trial
2.2 Pre-Clinical Studies
2.3 Different Stages of Clinical Trials
2.4 Basics Principles in Clinical Trial Design
2.5 The World Branded Pharmaceutical Market
2.6 Technological and Scientific Models for Clinical Trial
2.6.1 Usefulness of Electronic Data Capture Use
2.7 Demands for Cost-Efficient Pipeline
2.8 Clinical Trial for Biopharmaceuticals

3 Market Analyses for Clinical Trial Business
3.1 Global Clinical Trial Business
3.2 US Clinical Trial Business
3.3 European Clinical Trial Business
3.4 Increased Demand for Phase IIIb and IV Studies
3.5 Demand for Phase II and IIIa Studies Grows
3.6 Outsourcing Clinical Trial Business to CROs
3.7 Major CROs Take Half of the Market Share
3.8 Reasons for Outsourcing Clinical Trials
3.9 Clinical Trial Outsourcing to Countries in the Developing World
3.10 Summary of the Chapter

4 Outsourcing Clinical Research to CROs
4.1 SWOT Analysis for Outsourcing Clinical Trial
4.2 Growth of CRO Industry
4.3 Growth Rate of Major CROs
4.4 CRO Forming Alliances for Improving Market Share
4.5 Quintiles Allies with Thermo Fisher
4.6 CROs to Maintain High Quality
4.7 CROs in India
4.8 Quintiles Central Laboratory Facility to Facilitate Clinical Trials in Asia
4.9 MDS Pharma Services Expands Early-Phase Development
4.10 The Use of CROs in Drug Discovery and Development is Increasing as Big Pharma Changes
4.11 Clininvent is a CRO with Standardised Data Management Skills

5 Outsourcing Clinical Trials to Developing Countries
5.1 Selection of Developing Countries is for Cost-Savings
5.2 China Receives Renewed Attention
5.3 India Receives Renewed Attention
5.4 Drivers for Outsourcing Clinical Research Services from China and India
5.5 Restrains for Outsourcing Clinical Research Services from China and India
5.6 Factors for Patient Recruitment in China
5.7 Patient Recruitment is Quicker in Latin America
5.8 Outsourcing Clinical Data Management

6 Firsthand Interviews with Industry Opinion Leaders
6.1 Interview with Dr Tom Parke, Tessella
6.2 Interview with Dr Goran Gannedahl, NMCT
6.3 Interview with Dr Arun Bhatt, Clininvent
6.4 Interview with Dr Ernst Johannes, Quintiles
6.5 Interview with Dr Louis Christian Clauss, Baxter
6.6 Interview with Dr Venkat Jasti
6.7 Interview with Dr Valery Novikov, PRA International
6.8 Interview with Jay McTaggart
6.9 Interview with Patricia Moenaert, Progenitor International Research
6.10 Presentation at Clinical Trials 2008 Congress by Vinka Ljubimir, GlaxoSmithKline
6.11 Interview with David Eaton, Institute of Cancer Research and NHS
6.12 Interview with Dr Laura Brown, Cardiff University
6.13 Interview with Anne Maria Ylisaari, Orion
6.14 Interview with Carmen Salazar, Cellerix
6.15 Interview with Manish Badonia, Cadila

7 Patient Recruitment as a Factor for Successful Clinical Trial Business
7.1 Advertising to Provide Value

8 Drug Safety Issue in Clinical Trial
8.1 Safety Concerns and Development Pressures Will Change the Structure of Clinical Trials
8.2 Phase I and II Clinical Trials Will Incorporate More Complex Screening Techniques
8.3 Presentation at Clinical Trials 2008 Congress by Francis Ruiz, NICE
8.4 Presentation at Clinical Trials 2008 Congress by Dr Peter Feldschreiber, MHRA
8.5 Presentation at Clinical Trial Congress 2008 by Alison McAdams, Davies Arnold Cooper
8.6 GlaxoSmithKline's Clinical Trial Data Suggests Increased Suicide Risks among Subjects

9 Conclusions
9.1 The Contract Research Market is Dominated by a Few Companies
9.2 The Clinical Trial Market Outsourcing Will Increase in Revenue from 2008-2018
9.3 Prospects for Clinical Trial Business